Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.51 USD | -0.12% | -36.02% | -17.46% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.46% | 244M | |
+12.06% | 227B | |
+12.07% | 192B | |
+13.88% | 136B | |
+27.12% | 108B | |
+0.68% | 64.07B | |
+13.39% | 52.1B | |
+6.74% | 51.87B | |
+8.81% | 44.33B | |
+4.14% | 36.75B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Cantor Fitzgerald Starts Coverage on NeuroPace with Overweight Rating, $11 Price Target